AD-MSC-CM

N/A

Report date: 2025/01/26 19:02:42

Base Information

Drug NameAD-MSC-CM
Drug Alias Nameallogeneic adipose-derived mesenchymal stem cell therapy (Tithon Biotech/Summa Bio-Solutions)autologous adipose-derived mesenchymal stem cell therapy (Tithon Biotech/Summa Bio-Solutions)autologous/allogeneic adipose-derived mesenchymal stem cell therapy (Tithon Biotech/Summa Bio-Solutions)AD-MSC-CM
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Adipose stem cell therapyCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionImmunomodulatorsStem cells modulators
TargetsUpdating
Therapy Area/IndicationsRespiratory Distress Syndrome, AdultIdiopathic Pulmonary FibrosisAcute Lung Injury +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTithon Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesPaspa Pharmaceuticals Pty LtdTithon Biotech IncSumma Bio-Solutions Inc
Inactive CompaniesN/A
Active IndicationsRespiratory Distress Syndrome, AdultIdiopathic Pulmonary FibrosisAcute Lung Injury +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A